OrbusNeich has presented data from two studies demonstrating that the Genous Stent increases endothelial coverage and reduces thrombogenicity as compared to bare metal stents (BMS) by enhancing the specific binding of CD34+ endothelial progenitor cells (EPCs).
Genous is OrbusNeich’s patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents.
The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
The data showed that the Genous Stent bound more cells and had less thrombus than BMS and gene expression analysis showed that endothelial specific markers were increased and thrombogenic markers were decreased with the Genous Stent compared to BMS.
The data comparing the Genous Stent and BMS were further validated in an in-vitro coronary artery model infused with human peripheral blood CD34+ cells and human monocytes.
The in-vitro study demonstrated a higher affinity of CD34+ cells, which are associated with endothelialization, and a lower adhesion of monocytes, which are associated with inflammation, to the Genous Stent compared to BMS.
In a second study, increased cell coverage was observed for the Genous Stent compared to BMS in vivo.
The study was designed to investigate the gene expression patterns of endothelial specific genes and endothelial coverage by scanning electron microscopy and qPCR after stents were implanted in carotid arteries for seven days.
OrbusNeich Research and Development vice president Steve Rowland said that the data presented for each experimental model represent the mechanistic validation for Genous Stent and this is further evidence that the technology behind the Genous Stent accelerates the healing of the vessel wall and provides an important alternative to those patients with a high risk for thrombosis.